Multidisciplinary Association For Psychedelic Studies Website Links For
Multidisciplinary 		 

Information About

Multidisciplinary Association For Psychedelic Studies
  CATEGORIES ABOUT MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES
   
psychedelic research
   
APPAREL
BABY
BEAUTY
BOOKS
CAR TOYS
CELL PHONES
DVD'S
ELECTRONICS
GOURMET FOOD
GROCERIES
HEALTH & PERSONAL
HOME & GARDEN
JEWELRY
MUSIC
MUSIC INSTRUMENTS
OFFICE PRODUCTS
SOFTWARE
SPORTING GOODS
TOOLS & HARDWARE
TOYS
VIDEO GAMES
SHOPPING HOME
MORE SHOPPING...




ACHIEVEMENTS

Since 1995, MAPS has disbursed over two million dollars to worthy research and educational projects and has:

  • Obtained FDA and IRB approval to study MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD).

  • Sponsored efforts by Prof. Lyle Craker, Medicinal Plant Program, UMass Amherst Department of Plant and Soil Sciences, to obtain a license from the Drug Enforcement Administration for a marijuana production facility.

  • Sponsored pioneerig analytical research into the effects of the marijuana vaporizer, leading to the first human study of marijuana vaporizers conducted by Dr. Donald Abrams, UC San Francisco.

  • Opened an FDA Drug Master File for MDMA. This is required before any drug can be researched in FDA-approved human studies.

  • Assisted Dr. Charles Grob to design, obtain approval for and fund the first FDA-approved study in the U.S. to administer MDMA to humans.

  • Assisted in the design and is funding the world's first government-approved scientific study of the therapeutic use of MDMA (Spain).

  • Sponsored the first studies to analyze the purity and potency of street samples of "Ecstasy" and medical marijuana.

  • Funded the successful efforts of Dr. Donald Abrams to obtain approval for the first human study in 15 years into the therapeutic use of marijuana, along with a $1 million grant from the National Institute on Drug Abuse.

  • Obtained Orphan Drug designation from the FDA for smoked marijuana in the treatment of AIDS Wasting Syndrome.

  • Funded the synthesis of psilocybin for the first FDA-approved study in twenty-five years to evaluate psilocybin in a patient population.

  • Supported long-term follow-up studies of pioneering research with LSD and psilocybin originally conducted in the 1950s and 1960s.


Currently, MAPS has been given a Schedule I license to conduct research with MDMA on veterans suffering from Post Traumatic Stress Syndrome from the Afghan War as well as Cancer patients, the first licenses the DEA has granted for MDMA research.


EXTERNAL LINKS